Categories: CombinationSmart

Smart combination therapy for liver cancer tackles drug resistance

Credit: CC0 Public Domain

Liver cancer is one of the most common cancer types worldwide and is especially common in China. A collaborative effort between researchers at the Netherlands Cancer Institute and Shanghai using CRISPR/Cas has led to the discovery that insensitivity to a liver cancer drug can be prevented if it is given in combination with a second drug.

Finding the alternative pathway in the cancer cell

More and more —known as targeted therapy—inhibit the effects of DNA errors in the cell. Unfortunately, cancer cells often are—or become—resistant to these drugs. They then continue to divide via an alternative signaling route in the cell. Molecular cancer researcher Rene Bernards exposes these routes in cancer cells by blocking all routes off, one by one, using genetic techniques such as CRISPR/Cas.

Bernards first discovered one of these pathways in 2012. He wanted to know why a specific drug did nothing for a particular form of colon cancer that is difficult to treat, while working fine for melanoma involving exactly the same DNA mutation. Then he figured out that combining the first drug with a second blocks this pathway, a revolutionary discovery, which has led to a life-extending combination that is now used worldwide. It also led to a search for other alternative signaling pathways as well as new combination therapies for other types of cancer.

Combination therapy for liver cancer overcomes resistance

This week, Bernards, his Shanghai-based postdoc Haojie Jin, and their colleagues in Europe and China describe a similar resistance mechanism, in in the journal Nature. They discovered why the drug lenvatinib, one of the few targeted drugs on the market for liver cancer, shows no effect at all in 75-80 percent of patients.

The interferer turned out to be EGFR, a growth factor receptor, that—as the researchers observed—is activated in liver as soon as the drug lenvatinib is administered, thereby spurring cell division. In mouse models, the researchers then witnessed that precisely those tumors that were resistant to lenvatinib from the start, did indeed activate the EGFR.

But they also discovered that it is possible to override this resistance in as well as mice by combining lenvatinib with another drug, gefitinib, which inhibits EGFR. This is an existing that is already being used to treat lung cancer, for example.

Six hundred beds for liver cancer

Liver cancer is relatively rare in the West, although certain lifestyle factors have led to an increase in its occurrence. In Africa and Asia, however, liver cancer, mainly as a result of hepatitis B and C, is a major problem, and half of the world’s deaths related to liver cancer occur in China. Because Rene Bernards holds a part-time chair at Jiao Tong University in Shanghai postdoc Hoajie Jin’s home university, they were able to immediately set up an first-in-human clinical study at the Eastern Hepatobiliary Surgery Hospital in Shanghai. This hospital alone has 600 beds for patients with cancer.

Proof-of-concept study

This phase 1 proof-of-concept study involved twelve patients who previously did not respond to treatment with lenvatinib and who had large amounts of EGFR in their tumor. A significant reduction of the tumor was observed in four of the twelve. The cohort of patients is now being expanded to thirty. After that, larger clinical studies are needed before this can be us

Read More

News Bot

Share
Published by
News Bot

Recent Posts

West Indies batting implodes as Aussies grab ODI series lead

AUSTRALIA grabbed a 1-0 lead in the CG Insurance three-match One Day International series with…

31 mins ago

Killer blow: Knights’ injury crisis threatens season

Newcastle’s top eight hopes have taken a massive hit after they were mauled 48-4 by…

31 mins ago

Review: Old is a mostly solid film undermined by jarring twist ending

Time's wing'd chariot draws near — Director M. Night Shyamalan's latest film was inspired by…

32 mins ago

The best deals from PlayStation’s and Xbox’s latest summer game sales

Dealmaster — Dealmaster has deals on Mass Effect, Halo, The Last of Us, Returnal, and…

32 mins ago

Nuclear power’s reliability is dropping as extreme weather increases

Getting hotter — A comprehensive analysis shows that warmer temperatures aren't the only threat. K.…

32 mins ago

Apple and Roku have newly upgraded streaming remotes—are they worth buying?

A great remote in hand is worth two you'd want to throw in a bush…

32 mins ago